We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Language in Primary Progressive Aphasia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00537004
Recruitment Status : Recruiting
First Posted : September 28, 2007
Last Update Posted : January 25, 2023
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Marsel Mesulam, Northwestern University

Brief Summary:
The purpose of this study is to further define the neurological and linguistic deterioration in primary progressive aphasia.

Condition or disease
Primary Progressive Aphasia

Detailed Description:

The Language in Primary Progressive Aphasia (PPA) aims to understand the behavioral, anatomical and physiological changes in people with PPA throughout the course of the illness. The researchers in this study want to increase awareness of PPA, educate others about this unique disorder, and to encourage more research to eventually develop therapies.

During the three-day research program, participants will be asked to undergo neuropsychological testing (paper and pencil tests that evaluate cognition), advanced imaging (MRI and PET), cognitive experiments, and other computer and language testing batteries. Participants may be asked to return every two years to complete the same measures.

For participants not living near Chicago, IL, flights and accommodations (for both the person with PPA and their companion) will be covered by the study.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Asymmetric Neurodegeneration and Language in Primary Progressive Aphasia
Study Start Date : May 2007
Estimated Primary Completion Date : April 2027
Estimated Study Completion Date : April 2027

PPA (Primary Progressive Aphasia)
Individuals with primary progressive aphasia
Individuals with no diagnosis of any type of dementia

Primary Outcome Measures :
  1. Neuropsychological variables [ Time Frame: Immediately after testing and at two years post-testing ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Participants with PPA will be recruited from the Northwestern University Alzheimer's Disease Center Core registry, the Northwestern University Neurobehavior and Memory Clinic, and from those who contact the center that are interested in PPA research.

Inclusion Criteria:

  • Diagnosis of primary progressive aphasia
  • Right-handed
  • Native English speaker
  • Visual acuity of 20/30 corrected
  • Adequate hearing to follow conversation
  • Safe for an MRI scan

Exclusion Criteria:

  • Left-handedness
  • Claustrophobia
  • Presence of significant medical illness that initially or in the future could interfere with continued participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00537004

Layout table for location contacts
Contact: Seyi Adeolu 312-503-2398 PPA.Research@northwestern.edu

Layout table for location information
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Seyi Adeolu    312-503-2398    PPA.Research@northwestern.edu   
Principal Investigator: M.-Marsel Mesulam, MD         
Sponsors and Collaborators
Northwestern University
National Institute on Aging (NIA)
Layout table for investigator information
Principal Investigator: Marsel Mesulam, MD Northwestern University Feinberg School of Medicine
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Marsel Mesulam, Director, Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University
ClinicalTrials.gov Identifier: NCT00537004    
Other Study ID Numbers: IA0125
R01AG077444 ( U.S. NIH Grant/Contract )
First Posted: September 28, 2007    Key Record Dates
Last Update Posted: January 25, 2023
Last Verified: January 2023
Keywords provided by Marsel Mesulam, Northwestern University:
primary progressive aphasia
frontotemporal dementia
semantic dementia
progressive nonfluent aphasia
progressive aphasia
frontotemporal lobar degeneration
Additional relevant MeSH terms:
Layout table for MeSH terms
Aphasia, Primary Progressive
Pick Disease of the Brain
Frontotemporal Dementia
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Brain Diseases
Central Nervous System Diseases
Neurocognitive Disorders
Mental Disorders
Frontotemporal Lobar Degeneration
TDP-43 Proteinopathies
Neurodegenerative Diseases
Proteostasis Deficiencies
Metabolic Diseases